aTYR Pharma Inc.
aTYR Pharma Inc. is listed today as aTyr Pharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2017 | $46 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Mar 2015 | $76 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company aTyr Pharma, Inc., its revenue in fiscal 2024 came from these product and service lines: Collaboration Revenue $200,000 (85%).
Annual report (SEC XBRL) · Dec 2024
aTYR Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2017).
SEC Form D · Sep 2017
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2017
Products and services#
No products or services of aTYR Pharma Inc. are on record.
Investors#
20 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Partners Management VIII, LLC | Fund or asset manager | not stated | not stated | Held Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Alta Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| CHP II LP | Fund or asset manager | not stated | not stated | Held Series A, B, B-2, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| CHP II Management, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, B-2, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Domain Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| DP VIII Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| John K. Clarke | Person | not stated | not stated | Held Series E preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| John Mendlein | Person | not stated | not stated | Held Series C and D preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Polaris Venture Management Co. V, L.L.C. | Venture capital | not stated | not stated | Held Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Polaris Venture Partners Entrepreneurs' Fund V, L.P. | Venture capital | not stated | not stated | Held Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Polaris Venture Partners Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Polaris Venture Partners Special Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Polaris Venture Partners V, L.P. | Venture capital | not stated | not stated | Held Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Sofinnova Management IX, L.L.C. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Sofinnova Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 42 investors.
Largest shareholders today
Institutions holding aTyr Pharma, Inc. shares, as of Sep 30, 2026.
- Federated Hermes, Inc.$2 M4.72%
- Vanguard Capital Management LLC$1 M3.57%
- Gsa Capital Partners LLP$1 M3.25%
- Kalehua Capital Management LLC$1 M1.74%
- FMR LLC$1 M1.69%
- BlackRock, Inc.$0 M1.54%
- Jacobs Levy Equity Management, Inc$0 M1.31%
- Geode Capital Management, LLC$0 M1.15%
- UBS Group AG$0 M1.11%
- Morgan Stanley$0 M1.05%
- AQR Capital Management LLC$0 M0.66%
- Millennium Management LLC$0 M0.55%
- Vanguard Fiduciary Trust Co$0 M0.55%
- State Street Corp$0 M0.46%
- Squarepoint Ops LLC$0 M0.38%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| John D. Mendlein | Executive officer | Sep 2017 |
| John T. Blake | Executive officer | Sep 2017 |
| Nancy D. Krueger | Executive officer | Sep 2017 |
| Sanjay S. Shukla | Executive officer | Sep 2017 |
| Sanuj K. Ravindran | Executive officer | Sep 2017 |
| David C. Weiner | Executive officer | Apr 2015 |
| Frederic C. Chereau | Executive officer | Apr 2015 |
| Amir H. Nashat, Sc.D. | Director | Sep 2017 |
| James C. Blair | Director | Sep 2017 |
| Jeffrey S. Hatfield | Director | Sep 2017 |
| John D. Mendlein | Director | Sep 2017 |
| John K. Clarke | Director | Sep 2017 |
| Mark P. Goldberg | Director | Sep 2017 |
| Paul K. Schimmel | Director | Sep 2017 |
| Srini S. Akkaraju | Director | Sep 2017 |
| Timothy P. Coughlin | Director | Sep 2017 |
| Akkaraju C. Srinivas | Non-Management Director | Apr 2015 |
| Amir C. Nashat | Non-Management Director | Apr 2015 |
| Ed C. Penhoet | Non-Management Director | Apr 2015 |
| Kathryn C. Falberg | Non-Management Director | Apr 2015 |
| Paul C. Schimmel | Non-Management Director | Apr 2015 |
About
Company in San Diego, United States.
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.